Online inquiry

IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12090MR)

This product GTTS-WQ12090MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12090MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10634MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY-3303560
GTTS-WQ8639MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ5610MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CDP791
GTTS-WQ3951MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ15351MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA TRC-105
GTTS-WQ3787MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ4248MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIIB031
GTTS-WQ5468MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CDB-1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW